Aqua Bio Technology (ABTEC) H1 2025 earnings summary

Executive summary

• Underwent major restructuring, including divestment of prior acquisitions and a new focus on three product areas: skincare ingredients, product sales/distribution, and logistics solutions.

• Appointed a new CEO/CFO in August 2025 to drive reorganization and financial improvement.

• Activity and revenue from continuing operations declined in H1 2025, but management remains optimistic about market prospects.

Financial highlights

• Operating revenue for H1 2025 was NOK 7.7 million, down from NOK 12.1 million in H1 2024.

• EBITDA improved to NOK -11.9 million from NOK -15.4 million year-over-year.

• Operating loss was NOK -13.9 million, compared to NOK -17.8 million in H1 2024.

• Net result for the period was NOK -13.9 million, versus NOK -20.8 million in H1 2024.

• Result after tax from discontinued operations was NOK 89.0 million, reflecting reversal of previous loss provisions and adjustments.

Outlook and guidance

• Ongoing focus on cost control, operational efficiency, and value creation across the value chain.

• The company does not have sufficient capital to secure operations for the next 12 months and faces significant future liquidity needs.

• Board is actively working to secure liquidity and believes continued operations are possible despite uncertainty.